The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia.
Saved in:
| Title: | The PMDA Perspectives on New Oral Prolyl Hydroxylase Domain Enzyme Inhibitors for Renal Anemia. |
|---|---|
| Authors: | Tanaka M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Ikuma M; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Asakura W; Office of New Drug 1, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan., Fujiwara Y; Chief Executive, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. |
| Source: | Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2022 Feb; Vol. 111 (2), pp. 358-361. Date of Electronic Publication: 2021 May 16. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 0372741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-6535 (Electronic) Linking ISSN: 00099236 NLM ISO Abbreviation: Clin Pharmacol Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
